Swiss Venture Capital Report 2026 - Zurich Presentation (SECA (Swiss Private Equity and Corporate Finance Association))

Summary

• Swiss venture capital invested capital experienced an 8.5% decrease compared to pre-pandemic 2019 levels.p.3
• Invested amount in the top 20 rounds was 15% less than in the previous year.p.5
• Regional cantonal performance varied significantly, with financing in Geneva rising by 81.3% while Zug dropped by 47.3%.p.6
• Biotech investment capital grew by +50%, whereas Fintech suffered a decline of -52%.p.7
• Funding volume across phases dropped by -1% for Later Stage, -20% for Early Stage, and -19% for Seed Stage.p.9
• The overall median of round sizes reached 3m, reflecting a +41% increase.p.10
• Total European venture capital invested amount stood at EUR 56.7 billion across 9’600 rounds in 2024.p.25

Key insights

1. Healthcare IT recovered strongly from its 2023 low, recording an investment increase of +226%.p.7
2. ICT early stage volume grew by +91%, supported by 8 rounds exceeding 10 million.p.9
3. Concentration in top rounds reached its lowest point, with the Top 20 rounds accounting for 49% of total capital.p.10
4. Fundraising remained active with 46 open funds, including 25 first closings.p.14
5. Confidence among Swiss VC managers improved, with 76% expecting higher investment volume in Switzerland over the next 12 months.p.16
6. Exit activity remained sluggish with no IPO recorded in 2024.p.19
7. Foreign funding and capital-intensive deeptech startups served as major stabilizing factors during the crisis.p.20